Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
作者： Robert P. Giugliano , Marc S. Sabatine
DOI: 10.1016/J.JACC.2015.05.001
关键词:
摘要: … The catalytic subunit of PCSK9 binds to the epidermal growth … by PCSK9, gain-of-function mutations in PCSK9 resulting in its … As seen in the Mendelian randomization studies of loss-of-…
core.ac.uk
onlinejacc.org
elsevier.com参考文章(71)
Nihar R. Desai, Robert P. Giugliano, Jing Zhou, Payal Kohli, Ransi Somaratne, Elaine Hoffman, Thomas Liu, Robert Scott, Scott M. Wasserman, Marc S. Sabatine, AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program–Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients Journal of the American College of Cardiology. ,vol. 63, pp. 430- 433 ,(2014) , 10.1016/J.JACC.2013.09.048
Erik Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S. Rosenson, Gerald F. Watts, Eric Bruckert, Leslie Cho, Ricardo Dent, Beat Knusel, Allen Xue, Rob Scott, Scott M. Wasserman, Michael Rocco, Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance Journal of the American College of Cardiology. ,vol. 63, pp. 2541- 2548 ,(2014) , 10.1016/J.JACC.2014.03.019
Michael J. Koren, Pernille Lundqvist, Michael Bolognese, Joel M. Neutel, Maria Laura Monsalvo, Jingyuan Yang, Jae B. Kim, Rob Scott, Scott M. Wasserman, Harold Bays, Anti-PCSK9 Monotherapy for Hypercholesterolemia Journal of the American College of Cardiology. ,vol. 63, pp. 2531- 2540 ,(2014) , 10.1016/J.JACC.2014.03.018
Clapton S. Dias, Adam J. Shaywitz, Scott M. Wasserman, Brian P. Smith, Bing Gao, Dina S. Stolman, Caroline P. Crispino, Karen V. Smirnakis, Maurice G. Emery, Alexander Colbert, John P. Gibbs, Marc W. Retter, Blaire P. Cooke, Stephen T. Uy, Mark Matson, Evan A. Stein, Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. Journal of the American College of Cardiology. ,vol. 60, pp. 1888- 1898 ,(2012) , 10.1016/J.JACC.2012.08.986
, Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients New England Journal of Medicine. ,vol. 371, pp. 203- 212 ,(2014) , 10.1056/NEJMOA1300955
R. E. Hammer, Y.-A. Moon, J. D. Horton, S. Rashid, D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 5374- 5379 ,(2005) , 10.1073/PNAS.0501652102
Nabil G Seidah, PCSK9 as a therapeutic target of dyslipidemia Expert Opinion on Therapeutic Targets. ,vol. 13, pp. 19- 28 ,(2009) , 10.1517/14728220802600715
Patrick M. Moriarty, Terry A. Jacobson, Eric Bruckert, Paul D. Thompson, John R. Guyton, Marie T. Baccara-Dinet, Daniel Gipe, Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. Journal of Clinical Lipidology. ,vol. 8, pp. 554- 561 ,(2014) , 10.1016/J.JACL.2014.09.007
D J Rader, W Cain, K Ikewaki, G Talley, L A Zech, D Usher, H B Brewer, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. Journal of Clinical Investigation. ,vol. 93, pp. 2758- 2763 ,(1994) , 10.1172/JCI117292
Evan A. Stein, Narimon Honarpour, Scott M. Wasserman, Feng Xu, Rob Scott, Frederick J. Raal, Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia Circulation. ,vol. 128, pp. 2113- 2120 ,(2013) , 10.1161/CIRCULATIONAHA.113.004678